Ferring Pharmaceuticals
SAN FRANCISCO, June 1, 2010 - Data recently presented on FIRMAGON(R) (degarelix) hormonal therapy for
prostate cancer showed that long-term use beyond one year (median observation
time 840 days) continued to be effective and well tolerated.[1] Full details
were shared at the American Urological Association (AUA) 2010 Annual Meeting.
SAINT-PREX, Switzerland, May 10, 2010 - Ferring Pharmaceuticals today announced an agreement that will expand its
Women's Health product portfolio with the acquisition of the global rights to
Xanodyne Pharmaceutical's LYSTEDA(TM) (tranexamic acid), a first-in-class,
non-hormonal therapy indicated specifically for treatment of women with
cyclic heavy menstrual bleeding (HMB).
BARCELONA, April 21, 2010 - Health care professionals need to consider the impact of
prostate cancer on the 'whole man' rather than focusing on cancer treatment
in isolation, according to results from an international survey of prostate
cancer patients and their partners.
BARCELONA, Spain, April 19, 2010 - Study results discussed today at the European Association of
Urology (EAU) Congress in Barcelona have reinforced the association between
nocturia and a greater risk of falls and mortality.
SAINT-PREX, Switzerland, December 21 - Results from a phase III pivotal study sub-analyses reported in European
Urology show that prostate cancer patients who received Firmagon(R)
(degarelix) in the study have a statistically significant greater probability
of PSA (prostate-specific-antigen) recurrence-free survival compared with
those taking leuprolide (P=0.05).
